Dabigatran for Treatment and Secondary Prevention of Venous Thromboembolism in Pediatric Congenital Heart Disease

Dabigatran for Treatment and Secondary Prevention of Venous Thromboembolism in Pediatric Congenital Heart Disease

Background Congenital heart disease (CHD) is common in children and associated with greater risk of thrombotic complications. Management of these complications with standard‐of‐care treatment is suboptimal for these children. Methods and Results The effectiveness and safety of dabigatran were demons...

Full description

Bibliographic Details
Main Authors: Manuela Albisetti, Igor Tartakovsky, Jacqueline Halton, Lisa Bomgaars, Elizabeth Chalmers, Lesley G. Mitchell, Matteo Luciani, Ildar Nurmeev, Kirill Gorbatikov, Corinna Miede, Martina Brueckmann, Leonardo R. Brandão
Format: Article
Language:English
Published: Wiley 2024-02-01
Series:Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Subjects:
children
congenital heart disease
dabigatran
venous thromboembolism
Online Access:https://www.ahajournals.org/doi/10.1161/JAHA.122.028957

Internet

https://www.ahajournals.org/doi/10.1161/JAHA.122.028957

Similar Items